14 articles6,017 citations
Doxorubicin Alone versus Intensified Doxorubicin Plus Ifosfamide for First-Line Treatment of Advanced or Metastatic Soft-Tissue Sarcoma: A Randomised Controlled Phase 3 Trial
Judson, van der Graaf·Lancet Oncol·2014·1,181 citations
Soft Tissue and Visceral Sarcomas: Esmo–euracan–genturis Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up
Gronchi, Stacchiotti·Annals of Oncology·2021·901 citations
Survival and Prognosis with Osteosarcoma: Outcomes in More Than 2000 Patients in the EURAMOS-1 (european and American Osteosarcoma Study) Cohort.Citation only
Smeland, Marina·Eur J Cancer·2019·750 citations
Comparison of MAPIE versus MAP in Patients with a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (EURAMOS-1): An Open-Label, International, Randomised Controlled Trial.
Marina, Whelan·The Lancet. Oncology·2016·531 citations
Bone Sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up.Citation only
Strauss, Stacchiotti·Ann Oncol·2021·492 citations
Pexidartinib versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): A Randomised Phase 3 Trial
Tap, Wagner·Lancet·2019·480 citations
Chemotherapeutic Adjuvant Treatment for Osteosarcoma: Where Do We Stand?Citation only
Anninga, Egeler·Eur J Cancer·2011·470 citations
Nirogacestat, a Γ-Secretase Inhibitor for Desmoid Tumors.Citation only
Gounder, Kasper·N Engl J Med·2023·274 citations
Denosumab in Patients with Giant-Cell Tumour of Bone: A Multicentre, Open-Label, Phase 2 Study.Citation only
Chawla, Palmerini·Lancet Oncol·2019·257 citations
Giant Cell Tumour of Bone in the Denosumab Era.Citation only
van der Heijden, Gelderblom·Eur J Cancer·2017·174 citations
Higher Incidence Rates Than Previously Known in Tenosynovial Giant Cell Tumors.Citation only
Mastboom, Van de Sande·Acta Orthop·2017·156 citations
Comparison of Two Chemotherapy Regimens in Patients with Newly Diagnosed Ewing Sarcoma (EE2012): An Open-Label, Randomised, Phase 3 Trial.Citation only
Brennan, Wheatley·Lancet·2022·139 citations
Surgical Outcomes of Patients with Diffuse-Type Tenosynovial Giant-Cell Tumours: An International, Retrospective, Cohort Study.Citation only
Mastboom, van de Sande·Lancet Oncol·2019·132 citations
Vimseltinib versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.Citation only
Gelderblom, Tap·Lancet·2024·80 citations